Search Therapeutic Areas
About Us
Language
  • BELOW ARE THE SEARCH RESULTS

Advanced cancer

Pimasertib

A trial to determine if the amount of pimasertib that reaches the bloodstream is the same if taken as a tablet or a capsule

  • Phase
  • 1
See More Info
Study full name
Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients (EMR200066-013)
Study short name
A trial to determine if the amount of pimasertib that reaches the bloodstream is the same if taken as a tablet or a capsule
Drug(s)
Pimasertib
Therapeutic area
Disease or Medical Indication
Advanced cancer
Sponsor company
EMD Serono, Inc.
Codes
Protocol: EMR200066-013
National Clinical Trial: NCT01992874
EudraCT: Not Applicable
Study Design Summary
Key Words
Study dates
November 2013 to February 2015

Ovarian or peritoneal cancer

Pimasertib and SAR245409

Pimasertib plus SAR245409 in Ovarian Cancer

  • Phase
  • 2
See More Info
Study full name
Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated, Unresectable, Low-Grade Ovarian Cancer
Study short name
Pimasertib plus SAR245409 in Ovarian Cancer
Drug(s)
Pimasertib and SAR245409
Therapeutic area
Disease or Medical Indication
Ovarian or peritoneal cancer
Sponsor company
EMD Serono, Inc.
Codes
Protocol: EMR200066-012
National Clinical Trial: NCT01936363
EudraCT: Not Applicable
Study Design Summary
Key Words
Study dates
September 2012 to May 2015

Breast cancer

Gemcitabine (Gemzar®) + Bevacizumab (Avastin®)

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

  • Phase
  • 3
See More Info
Study full name
A Phase 2 Study of Gemcitabine and Bevacizumab as First-Line Treatment in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Previously Treated With Taxanes
Study short name
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
Drug(s)
Gemcitabine (Gemzar®) + Bevacizumab (Avastin®)
Therapeutic area
Disease or Medical Indication
Breast cancer
Sponsor company
Eli Lilly and Company
Codes
Protocol: B9E-US-S379
National Clinical Trial: NCT00623233
EudraCT: Not Applicable
Study Design Summary
Key Words
Study dates
March 2008 to January 2011
Afrikaans Afrikaans Shqip Shqip አማርኛ አማርኛ العربية العربية Հայերեն Հայերեն Azərbaycan dili Azərbaycan dili Euskara Euskara Беларуская мова Беларуская мова বাংলা বাংলা Bosanski Bosanski Български Български Català Català Cebuano Cebuano Chichewa Chichewa 简体中文 简体中文 繁體中文 繁體中文 Corsu Corsu Hrvatski Hrvatski Čeština‎ Čeština‎ Dansk Dansk Nederlands Nederlands English English Esperanto Esperanto Eesti Eesti Filipino Filipino Suomi Suomi Français Français Frysk Frysk Galego Galego ქართული ქართული Deutsch Deutsch Greek Greek ગુજરાતી ગુજરાતી Kreyol ayisyen Kreyol ayisyen Harshen Hausa Harshen Hausa Ōlelo Hawaiʻi Ōlelo Hawaiʻi עִבְרִית עִבְרִית हिन्दी हिन्दी Hmong Hmong Magyar Magyar Íslenska Íslenska Igbo Igbo Bahasa Indonesia Bahasa Indonesia Gaelige Gaelige Italiano Italiano 日本語 日本語 Basa Jawa Basa Jawa ಕನ್ನಡ ಕನ್ನಡ Қазақ тілі Қазақ тілі ភាសាខ្មែរ ភាសាខ្មែរ 한국어 한국어 كوردی‎ كوردی‎ Кыргызча Кыргызча ພາສາລາວ ພາສາລາວ Latin Latin Latviešu valoda Latviešu valoda Lietuvių kalba Lietuvių kalba Lëtzebuergesch Lëtzebuergesch Македонски јазик Македонски јазик Malagasy Malagasy Bahasa Melayu Bahasa Melayu മലയാളം മലയാളം Maltese Maltese Te Reo Māori Te Reo Māori मराठी मराठी Монгол Монгол ဗမာစာ ဗမာစာ नेपाली नेपाली Norsk bokmål Norsk bokmål پښتو پښتو فارسی فارسی Polski Polski Português Português ਪੰਜਾਬੀ ਪੰਜਾਬੀ Română Română Русский Русский Samoan Samoan Gàidhlig Gàidhlig Српски језик Српски језик Sesotho Sesotho Shona Shona سنڌي سنڌي සිංහල සිංහල Slovenčina Slovenčina Slovenščina Slovenščina Afsoomaali Afsoomaali Español Español Basa Sunda Basa Sunda Kiswahili Kiswahili Svenska Svenska Тоҷикӣ Тоҷикӣ தமிழ் தமிழ் తెలుగు తెలుగు ไทย ไทย Türkçe Türkçe Українська Українська اردو اردو O‘zbekcha O‘zbekcha Tiếng Việt Tiếng Việt Cymraeg Cymraeg isiXhosa isiXhosa יידיש יידיש Yorùbá Yorùbá Zulu Zulu